Literature DB >> 19699472

Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism.

Panos Roussos1, Stella G Giakoumaki, Panos Bitsios.   

Abstract

BACKGROUND: The functional catechol-O-methyltransferase (COMT) valine158methionine (val158met) polymorphism determines prepulse inhibition (PPI) levels and working memory performance and the effects of tolcapone on these functions. Here, we explored the effects of the synonymous COMT rs4818 C/G polymorphism and tolcapone on PPI and working memory.
METHODS: Thirteen G/G (low prefrontal cortex [PFC] dopamine [DA]) and 12 C/C (high PFC DA) healthy male subjects entered and completed the study. Subjects participated in two weekly sessions associated with either acute oral tolcapone (200 mg) or placebo according to a balanced, crossover, double-blind design. Prepulse inhibition was assessed with 5 dB and 15 dB above background prepulses at 30-msec, 60-msec, and 120-msec intervals. Subjective mood and working memory performance (n-back and letter-number sequencing) were also assessed.
RESULTS: Prepulse inhibition was lower and reaction time in the n-back was slower in the G/G compared with the C/C group in the placebo condition. Tolcapone increased PPI and improved performance in both working memory tasks in the G/G group only. Baseline startle was greater in the C/C group and was not affected by tolcapone. Mood profile was worse in the C/C group and tended to deteriorate with tolcapone. Status of val158met alone could not explain these results.
CONCLUSIONS: Catechol-O-methyltransferase haplotype analyses are essential in future research. Prepulse inhibition and working memory may both relate to PFC DA levels according to an inverted U-shaped curve function. Tolcapone could be potentially useful in the treatment of conditions with deficient sensorimotor gating and working memory such as schizophrenia and prodromal states but only in a genotype-specific manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699472     DOI: 10.1016/j.biopsych.2009.07.008

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  27 in total

1.  Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington.

Authors:  G Stennis Watson; Brenna A Cholerton; Rachel G Gross; Daniel Weintraub; Cyrus P Zabetian; John Q Trojanowski; Thomas J Montine; Andrew Siderowf; James B Leverenz
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

Review 2.  Towards medication-enhancement of cognitive interventions in schizophrenia.

Authors:  Hsun-Hua Chou; Elizabeth Twamley; Neal R Swerdlow
Journal:  Handb Exp Pharmacol       Date:  2012

3.  Influence of catechol-O-methyltransferase (COMT) gene polymorphisms in pain sensibility of Brazilian fibromialgia patients.

Authors:  Flávia Regina Barbosa; Josie Budag Matsuda; Mendelson Mazucato; Suzelei de Castro França; Sônia Marli Zingaretti; Lucienir Maria da Silva; Nilce Maria Martinez-Rossi; Milton Faria Júnior; Mozart Marins; Ana Lúcia Fachin
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

4.  Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice.

Authors:  Anne Tammimäki; Mikko Käenmäki; Oleg Kambur; Natalia Kulesskaya; Tiina Keisala; Eeva Karvonen; J Arturo García-Horsman; Heikki Rauvala; Pekka T Männistö
Journal:  Psychopharmacology (Berl)       Date:  2010-07-09       Impact factor: 4.530

Review 5.  Epigenetics and biomarkers in the staging of neuropsychiatric disorders.

Authors:  Trevor Archer; Richard J Beninger; Tomas Palomo; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 6.  Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls.

Authors:  Mary Falcone; Ryan M Smith; Meghan J Chenoweth; Abesh Kumar Bhattacharjee; John R Kelsoe; Rachel F Tyndale; Caryn Lerman
Journal:  Neuropsychopharmacology       Date:  2013-06-24       Impact factor: 7.853

7.  Tolcapone addition improves Parkinson's disease associated nonmotor symptoms.

Authors:  Thomas Müller
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

Review 8.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.

Authors:  Thomas Müller; Paul Foley
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

10.  Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults.

Authors:  Hsun-Hua Chou; Jo A Talledo; Sarah N Lamb; Wesley K Thompson; Neal R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2013-01-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.